CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 92 target
Drug / intervention
Propranolol Oral Product +2 moredrug
Likely dose
Not stated in record
Key inclusion· 8
  • Children aged 7-12 years
  • CPTS-RI total score ≥40
  • Primary diagnosis of PTSD, 6 months or more after traumatic event
  • Heart rate ≥55 bpm
Key exclusion· 20
  • Age <7 years or ≥13 years
  • Parents deprived of parental authority
  • Contraindications to propranolol including cardiogenic shock, sinus bradycardia, hypotension, heart block, heart failure, bronchial asthma, hypersensitivity
  • Concurrent medications with interactions with propranolol

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04985344
NCT04985344Phase 3RecruitingOn TrackUpdated 34mo ago
Long Recruiting

Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol: A Randomized Placebo-controlled Trial. PPP

University Hospital, Toulouse·interventional·Posted Aug 2, 2021·Updated Aug 28, 2023

In Brief

A Phase 3 clinical trial evaluating Propranolol Oral Product, Placebo, and 1 other intervention for PTSD. Currently recruiting, targeting 92 participants across 1 site.

Detailed Summary

By age 18, roughly 8% of traumatized youth have met criteria for a diagnosis of PTSD, with numbers rising up to 40% in cases of sexual abuse and assault. To date there is no empirical support for the use of psychopharmacological interventions as treatment of pediatric PTSD. Trauma-focused psychotherapeutic/TFP approaches should be favored in childhood PTSD. However, when compared to active control conditions, TFP produced a mean effect size on child and adolescents population (g=0.83). Moreover, in therapies with a substantial exposure component, the intense and lengthy reexperiencing of the traumatic event results in a substantial proportion of participants dropping out. The reactivation of a previously consolidated memory can make it labile, subsequently requiring a re-stabilization of it called reconsolidation of the memory. Acting on these reconsolidation processes makes possible to interfere with the subsequent storage of this memory.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPTSD
CountriesFrance
Collaborators--

Timeline

Phase 3Recruiting
202220232024202520262027
First PostedAug 2, 2021
Enrollment StartFeb 1, 2023
Primary CompletionSep 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 4.9 years agoPrimary completion in 1.2 years

Interventions

Propranolol Oral Productdrug

Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.

Placebodrug

Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.

memory reactivationother

90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.